Table 2.
Type and number of biologics used by colorectal cancer patients.
| 2010 | 2014 | ||||
|---|---|---|---|---|---|
| GePaRD (Germany) | PHARMO (Netherlands) | GePaRD (Germany) | PHARMO (Netherlands) | Caserta LHU (Italy) | |
| N = 2,162 | N = 112 | N = 2,362 | N = 73 | N = 49 | |
| Biologics used during 30 months of follow-upa [percent] | |||||
| Bevacizumab | 80.5 | 92.9 | 76.3 | 84.9 | 81.6 |
| Cetuximab | 39.1 | 1.8 | 32.7 | 4.1 | 24.5 |
| Panitumumab | 19.7 | 16.1 | 24.1 | 28.8 | 6.1 |
| Number of different biologics used during 30 months follow-up [percent] | |||||
| One | 69.9 | 89.3 | 78.2 | 82.2 | 87.8 |
| Two | 23.3 | 10.7 | 19.4 | 17.8 | 12.2 |
| More than two | 6.8 | 0.0 | 2.4 | 0.0 | 0.0 |
a
Since use of multiple drugs per patient was possible, numbers may add up to more than 100%.